Treatment of epidermal growth factor receptor-tyrosine kinase inhibitor in advanced non-small cell lung cancer and lung cancer with brain metastasis

Abstract

Objective To explore the efficacy,prognosis,and side effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for advanced non-small cell lung cancer and lung cancer with brain metastasis.Methods Clinical datas of advanced non-small cell lung cancer who received EGFR-TKI treatment in Fujian Provincial Hospital from January 2007 to August 2012 were retrospectively analyzed.All patients received EGFR-TKI until the disease progression or intolerable toxicity.Results The objective response rate (ORR) and the disease control rate (DCR) after administration of EGFR-TKI were 34.6％ (18/52) and 75.0％ (39/52),respectively.The median progression free survival time and overall survival time were six months and 18 months,respectively.The DCR in patients with adenocarcinoma,non-smoking,and tumor size ＜5 cm was higher than that in patients with non-adenocarcinoma,smokers and tumor size ≥ 5 cm (P ＜ 0.05).Survival analysis suggested that the median progression survival in patients with tumor size ＜5 cm and stable disease was longer than that in patients with tumor size ≥ 5 cm and progression disease (P ＜ 0.05).The median survival time in non-smokers and patients of tumor size ＜ 5 cm was longer than that in smokers and patients of tumor size ≥5 cm (P ＜0.05).Among 21 cases of lung cancer with brain metastasis treated with EGFR-TKI,overall ORR and DCR of intracranial lesions were 38.1 ％ and 90.5 ％,respectively.The ORR and DCR of systemic disease were 38.1％ and 85.7％,respectively.The most common side effects were rash (25.0 ％) and pruitus (19.2 ％).Conclusions EGFR-TKI is effective and safe in the treatment of advanced non-small cell lung cancer patients.EGFR-TKI may be effective on brain metastases in lung cancer patients. Key words: Epidermal growth factor receptor-tyrosine kinase inhibitor; Non-small cell lung cancer; Efficacy; Prognosis